echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > [Fast News] The third live broadcast of the "Precision Medicine" series was successfully concluded. A number of big coffee experts shared the research progress of multiple myeloma and the application of MRD!

    [Fast News] The third live broadcast of the "Precision Medicine" series was successfully concluded. A number of big coffee experts shared the research progress of multiple myeloma and the application of MRD!

    • Last Update: 2022-04-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On March 24th, the third live broadcast of the "Drug Precision" series of "Focus on Drug Target Accompaniment" co-planned by Genetron Health and Translational Medicine Network ended successfully.
    This live broadcast invited clinical authoritative experts in the field of malignant hematology, blood From a technical point of view, combined with actual clinical practice, Xue Da coffee and the leader of the clinical research and development team introduced the research progress of multiple myeloma and the application of MRD in detail
    .

    First, Professor Xiao Min, Deputy Director of the Department of Hematology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, gave a report entitled "Progress in MRD Monitoring of Multiple Myeloma"
    .

    Professor Xiao's lecture was divided into four parts.
    First, she systematically explained the guidelines for the diagnosis and treatment of multiple myeloma in plasma cell diseases, common abnormal indicators, prognosis, and MRD monitoring methods
    .

    In practical applications, Professor Xiao suggested to combine Ig-TCR high-throughput sequencing (NGS) with flow cytometry
    .

    Professor Xiao combined IMWG and literature reports to describe the evaluation criteria of MRD detection for MM remission and its guiding significance for prognosis
    .

    The results of clinical practice show that MRD is a very critical indicator, and achieving continuous negative MRD is of great significance to the prognosis and life of patients
    .

    Therefore, in order to save costs such as samples and time, it is necessary to improve the MRD detection technology and platform
    .

    Then, Professor Xiao described the MRD monitoring mode and monitoring standard of Tongji Hospital based on his own clinical practice methods
    .

    One of the most commonly used is Ig-TCR high-throughput sequencing (NGS), which will be developed into a routine MRD monitoring method in the future
    .

    Finally, Professor Xiao explained the practical application of MRD monitoring methods through 8 cases, and expressed his expectations for future MRD monitoring programs
    .

    Professor Xiao Min is currently the deputy director of the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
    His main research direction is molecular diagnosis of hematological malignancies; he presides over two National Natural Science Foundation of China, and participates in the National Natural Science Foundation of China and provincial and municipal funds as the main staff.
    He has published many SCI articles in journals such as Cancer Immuno Research, JITC and Blood
    .

    He has rich practical experience in molecular detection of blood diseases, especially in cutting-edge technologies such as NGS, Nanostring and liquid biopsy
    .

    Xiao Min, Department of Hematology, Tongji Hospital, followed by Mr.
    Jia Yehui, Senior Medical Director of Nanjing Legend Bio's Clinical Development, gave unique insights on "the latest clinical research progress of CAR-T therapy for multiple myeloma"
    .

    First, Mr.
    Jia systematically introduced the historical process of CAR-T therapy and the development of CAR-T targeting BCMA
    .

    Mr.
    Jia expects that there will be more CAR-T drugs with better efficacy for multiple myeloma in the future
    .

    Then, Mr.
    Jia introduced two approved CAR-T therapies for the treatment of multiple myeloma and their efficacy: Idecabtagene Vicleucel (Abecma) from Bristol-Myers Squibb and Ciltacabtagene autoleucel (Carvykti) from Legend Bio
    .

    Then, Mr.
    Jia explained the safety and efficacy of LCAR-B38M CAR-T cell therapy and cilta-cel therapy for multiple myeloma through the data of LEGEND-2, CARTITUDE-1 and CARTITUDE-2 studies
    .

    The data show a manageable safety profile, with high ORR and deep remission, and prolonged mPFS
    .

    Mr.
    Jia Yehui is currently the senior medical director of clinical development of Nanjing Legend Bio, responsible for the clinical development of LCAR-B38M and other pipeline products in China.
    He has served as the medical affairs manager in Novartis Oncology Division, Shanghai Roche, and Novartis Biomedical Research Institute, respectively.
    The head of medical affairs in the field of blood diseases and the deputy director of clinical development.
    In the field of hematology, he was responsible for the medical strategies and plans of Gleevec/Dashina/Jiekewei/Enriger/Rituxan, post-marketing clinical research and the Communication and maintenance of important hematology experts in the field
    .

    After Jia Yehui of Nanjing Legend Bio, Professor An Gang, Chief Physician of the Hospital of Hematology, Chinese Academy of Medical Sciences, shared with you the "clinical value of residual minimal lesions in multiple myeloma"
    .

    First, Professor An introduced the importance of MRD detection
    .

    It has been found through clinical practice that the prognostic value of CR largely depends on MRD status, and MRD-negative patients have better long-term survival
    .

    Therefore, MRD negativity is a key dynamic prognostic indicator in multiple myeloma, especially in high-risk multiple myeloma patients
    .

    Then, Professor An gave a detailed description of the clinical guidance of MRD detection
    .

    Taking MRD negativity as the treatment goal for patients with multiple myeloma can help to formulate and adjust individualized treatment plans for patients at various stages of the treatment process and improve the prognosis of patients
    .

    Subsequently, Professor An said that MRD detection has certain limitations
    .

    From a technical point of view, the detected local MRD status is not necessarily representative of the whole body
    .

    From a theoretical point of view, whether MRD negativity will ensure long-term survival of patients is still a controversial issue
    .

    At present, there are insufficient data to change treatment based on MRD results
    .

    Professor An Gang is mainly engaged in clinical and basic research on lymphoma and multiple myeloma
    .

    In terms of clinical research, Professor An Gang has established a complete clinical diagnosis and treatment system for multiple myeloma.
    Based on the current status of diagnosis, treatment and research of multiple myeloma in China, combined with international progress and development trends, he has established a complete set of MM diagnosis and treatment system suitable for national conditions.
    It has been widely used in the country
    .

    In terms of basic research, he is mainly devoted to the study of multiple myeloma genetics and immune microenvironment, which provides a good experimental and theoretical basis for further research on effective treatment strategies for MM
    .

    Finally, An Gang entered the discussion session
    .

    This session was chaired by Professor An Gang.
    During this process, the three sharing guests focused on "Advantages and Limitations of Different MRD Technology Platforms", "The Value of Biomarker in the R&D of New Hematological Cancer Drugs", and "The Development of MRD Detection in the Future" Three issues were discussed vigorously
    .

    The collision of ideas between the three big coffees is not to be missed! Discussion If you missed this live broadcast, you can join the "Medicine Precision" WeChat communication group to get the link to watch it back
    .

    Scan the QR code below to add a staff member's WeChat, and you will be invited to join the group.
    Please note "name+unit+department"
    .

    This live broadcast ended successfully with the unfulfilled expectations of all the guests and the audience! Precision medicine, diagnosis first, this series of live broadcasts aims to promote academic exchanges on innovative drug R&D, facilitate high-quality R&D of innovative drugs, and jointly promote the R&D exploration and industry thinking of Chinese pharmaceutical innovative enterprises
    .

    The "Medicine Accuracy" column uses a combination of online live broadcasts and offline meetings.
    It is a monthly issue.
    You are welcome to continue to obtain live broadcast information through the official account of Translational Medicine.
    Join the discussion! Thank you for your attention, see you in the fourth issue of April! Previous Issues Review of the first issue of "Medicine Precision": MRD's regulation, value and clinical application The second issue of "Medicine Precision": MRD detection and development of CAR-T cell therapy
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.